Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 4:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 3,988 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Small-Cell Lung Cancer (SCLC) Clear all
Recruiting Phase 2 Interventional

A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain

NCT05419076
View directory record Official record
Conditions
Lung Cancer, Lung Cancer Metastatic, Brain Metastases, Brain Metastases, Adult, Small-cell Lung Cancer, Small Cell Lung Carcinoma
Interventions
Stereotactic Radiosurgery, Cerebrospinal fluid collection
Radiation · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 14, 2026, 4:14 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC

NCT02382406
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Carboplatin, Nab-paclitaxel, MK-3475 (Phase I), MK-3475 (Phase II)
Drug
Lead sponsor
Nisha Mohindra, MD
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
5
States / cities
Duarte, California • Chicago, Illinois • Indianapolis, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Oct 14, 2026, 4:14 PM EDT
Not listed Phase 1 Interventional

Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer

NCT03396497
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
LYC-55716, Pembrolizumab
Drug
Lead sponsor
Lycera Corp.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Aurora, Colorado • Ann Arbor, Michigan • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 14, 2026, 4:14 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

NCT05074810
View directory record Official record
Conditions
Non Small Cell Lung Cancer, KRAS Activating Mutation
Interventions
avutometinib and sotorasib, avutometinib and sotorasib and defactinib
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
20
States / cities
Boulder, Colorado • Washington D.C., District of Columbia • Arlington Heights, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 14, 2026, 4:14 PM EDT
Completed Phase 2 Interventional

Immunotherapy SBRT Sensitization of the Programmed Death-1 (PD-1) Effect

NCT03825510
View directory record Official record
Conditions
Metastatic Nonsmall Cell Lung Cancer, Non Small Cell Lung Cancer
Interventions
Stereotactic Body Radiotherapy
Radiation
Lead sponsor
Crozer-Keystone Health System
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Oct 14, 2026, 4:14 PM EDT
Terminated Phase 3 Interventional Results available

LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research

NCT02231164
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
docetaxel, placebo, nintedanib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
9
States / cities
Chandler, Arizona • Fayetteville, Arkansas • Highland, California + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 14, 2026, 4:14 PM EDT
Completed Phase 1Phase 2 Interventional Results available

BIO 300 Non-Small Cell Lung Cancer Study

NCT02567799
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
BIO 300 Oral Suspension, Paclitaxel, Carboplatin, Radiotherapy
Drug · Radiation
Lead sponsor
Humanetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
4
States / cities
Baltimore, Maryland • Detroit, Michigan • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Oct 14, 2026, 4:14 PM EDT
Active, not recruiting Phase 2 Interventional

THIO Sequenced With Cemiplimab in Advanced NSCLC

NCT05208944
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
6-Thio-2'-Deoxyguanosine, Cemiplimab
Drug
Lead sponsor
Maia Biotechnology
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Birmingham, Alabama • Florham Park, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 14, 2026, 4:14 PM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

NCT06810544
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme, Glioma, Malignant, Solid Tumor, Non-Small Cell Adenocarcinoma, Lung Cancer, Brain Tumor
Interventions
TNG456, abemaciclib
Drug
Lead sponsor
Tango Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
15
States / cities
Scottsdale, Arizona • Irvine, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 14, 2026, 4:14 PM EDT
Recruiting Phase 1 Interventional

A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer

NCT06807632
View directory record Official record
Conditions
Extensive-stage Small-cell Lung Cancer
Interventions
Valemetostat, Atezolizumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 14, 2026, 4:14 PM EDT
Completed Phase 1 Interventional

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

NCT05585034
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma, Non-small Cell Lung Cancer, Squamous or Non-squamous, Urothelial Carcinoma, Renal Cell Carcinoma, Clear Cell, Castration-resistant Prostate Cancer, Ovarian Cancer, Epithelial, TNBC - Triple-Negative Breast Cancer, Colorectal Cancer
Interventions
XmAb®808, Keytruda® (pembrolizumab)
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
12
States / cities
Los Angeles, California • Denver, Colorado • Sarasota, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 14, 2026, 4:14 PM EDT
Completed Phase 2 Interventional

Phase II Study of Cetuximab in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer

NCT00251498
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Cetuximab
Drug
Lead sponsor
Veeda Oncology
Other
Eligibility
18 Years and older
Enrollment
82 participants
Timeline
Ends 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2008 · Synced Oct 14, 2026, 4:14 PM EDT
Active, not recruiting Phase 1 Interventional

Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)

NCT03319940
View directory record Official record
Conditions
Small Cell Lung Carcinoma
Interventions
Tarlatamab, Pembrolizumab, CRS Mitigation Strategies
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
15
States / cities
Duarte, California • New Haven, Connecticut • Tampa, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 14, 2026, 4:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Circulating Tumor Cells in Non-Small Cell Lung Carcinoma

NCT01830426
View directory record Official record
Conditions
Primary Lung Cancer
Interventions
Not listed
Lead sponsor
Epic Sciences
Industry
Eligibility
19 Years and older
Enrollment
232 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
3
States / cities
La Jolla, California • New Haven, Connecticut • Billings, Montana
Source: ClinicalTrials.gov public record
Updated Jan 22, 2016 · Synced Oct 14, 2026, 4:14 PM EDT
Completed No phase listed Observational

Pilot Study of a Novel Type of CT Scan to Assess Treatment Response During Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer

NCT02053285
View directory record Official record
Conditions
Non-small Cell Lung Cancer Stage III
Interventions
Not listed
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 23, 2022 · Synced Oct 14, 2026, 4:14 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC

NCT02905591
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Non-Small-Cell Lung Carcinoma, NSCLC
Interventions
Radiation Therapy, Paclitaxel, Carboplatin, Ascorbic Acid
Drug
Lead sponsor
Joseph J. Cullen, MD, FACS
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 14, 2026, 4:14 PM EDT
Recruiting Phase 2 Interventional

Repositioning Immunotherapy in VetArans With Lung Cancer

NCT06275360
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Nivolumab
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
7
States / cities
West Haven, Connecticut • Washington D.C., District of Columbia • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 14, 2026, 4:14 PM EDT
Recruiting Not applicable Interventional

Segmentectomy After Induction Therapy (SAINT)

NCT06496659
View directory record Official record
Conditions
Segmentectomy
Interventions
Segmentectomy
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 14, 2026, 4:14 PM EDT
Completed Phase 1 Interventional

PH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel/ Carboplatin As 1st Line Chemotherapy In NSCLC Patients

NCT00174356
View directory record Official record
Conditions
Carcinoma, Non-Small Cell Lung
Interventions
CI 1033, PACLITAXEL, CARBOPLATIN
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
6
States / cities
Tampa, Florida • Park Ridge, Illinois • Skokie, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2006 · Synced Oct 14, 2026, 4:14 PM EDT
Completed Phase 1 Interventional

Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors

NCT02014337
View directory record Official record
Conditions
Breast Cancer, Ovarian Epithelial Cancer Recurrent, Sarcoma, Non-small Cell Lung Cancer, Carcinoma, Transitional Cell, Prostate Cancer, Prostatic Neoplasms
Interventions
Mifepristone and Eribulin in combination
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
11
States / cities
Tucson, Arizona • Tampa, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 14, 2026, 4:14 PM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab Alone and In Combination With Acalabrutinib (ACP-196) in Subjects With Advanced Non-small Cell Lung Cancer

NCT02448303
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Pembrolizumab, Acalabrutinib
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Goodyear, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 14, 2026, 4:14 PM EDT
Withdrawn Phase 1 Interventional

Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC)

NCT07073183
View directory record Official record
Conditions
Squamous NSCLC
Interventions
CV09070101 mRNA vaccine (CVHNLC) 50 µg, CV09070101 mRNA vaccine (CVHNLC) 100 µg, CV09070101 mRNA vaccine (CVHNLC) 200 µg, CV09070101 mRNA vaccine (CVHNLC) 400 µg
Biological
Lead sponsor
CureVac
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Fairfax, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 14, 2026, 4:14 PM EDT
Completed Phase 1 Interventional

Cisplatin in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer or Lung Metastasis

NCT01014598
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Lung, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Adult Soft Tissue Sarcoma, Stage IV Non-Small Cell Lung Cancer
Interventions
Cisplatin, Pharmacological Study
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Oct 14, 2026, 4:14 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

NCT00006378
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, radiation therapy
Drug · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
3
States / cities
Morristown, New Jersey • New Brunswick, New Jersey • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Oct 14, 2026, 4:14 PM EDT